| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington 98195; 2 Division of Nephrology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710 Korea; 3 Transplant Research Laboratory, Solid Organ Transplant Service, Legacy Good Samaritan Hospital, Portland, Oregon 97201; and 4 Scios Incorporated, Sunnyvale, California 94086
Recent studies have demonstrated a role for microvascular and tubulointerstitial injury in some models of salt-sensitive hypertension. We utilized a model of post-cyclosporin A (CsA) nephropathy and hypertension to test the hypothesis that treatment with an angiogenic factor aimed at ameliorating the microvascular and renal injury would prevent the development of hypertension. CsA was administered with a low-salt diet for 45 days, resulting in a renal lesion characterized by afferent arteriolopathy, focal peritubular capillary loss, and tubulointerstitial fibrosis. Rats were then placed on a high-salt diet and randomized to receive either vascular endothelial growth factor (VEGF121) or vehicle for 14 days. Placement of rats with established CsA nephropathy on a high-salt diet results in the rapid development of salt-sensitive hypertension. VEGF121 treatment resulted in lower blood pressure, and this persisted on discontinuing the VEGF. VEGF121 treatment was also associated with a decrease in osteopontin expression, macrophage infiltration, and collagen III deposition and markedly stimulated resolution of the arteriolopathy (20.9 ± 7.8 vs. 36.9 ± 6.1%, VEGF vs. vehicle, P < 0.05). In conclusion, CsA-associated renal microvascular and tubulointerstitial injury results in the development of salt-sensitive hypertension. Treatment of animals with established CsA nephropathy with VEGF reduces the hypertensive response and accelerates histological recovery. The vascular protective effect of VEGF may be due to the improvement of arteriolopathy. Angiogenic growth factors may represent a novel strategy for treating CsA-associated hypertension and renal disease.
salt-sensitive hypertension; arteriolopathy
This article has been cited by other articles:
|
|
 |
|
  J.-W. Gu, R. D. Manning Jr., E. Young, M. Shparago, B. Sartin, and A. P. Bailey Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2009; 297(1): R142 - R148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Leonard, J. L. Friedrich, and D. P. Basile VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1648 - F1657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407. [Full Text] [PDF]
|
|
|
|
|
|
T. Nakagawa Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease Am J Physiol Renal Physiol, June 1, 2007; 292(6): F1665 - F1672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Tostivint, S. T. du Montcel, M. C. Jaudon, A. Mallet, P. Le Hoang, B. Bodaghi, G. Deray, and C. I. Bagnis Renal outcome after ciclosporin-induced nephrotoxicity Nephrol. Dial. Transplant., March 1, 2007; 22(3): 880 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Burt, M. S. Forbes, B. A. Thornhill, S. C. Kiley, J. J. Minor, and R. L. Chevalier Renal vascular endothelial growth factor in neonatal obstructive nephropathy. II. Exogenous VEGF Am J Physiol Renal Physiol, January 1, 2007; 292(1): F168 - F174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Long, W. Mu, K. L. Price, C. Roncal, G. F. Schreiner, A. S. Woolf, and R. J. Johnson Vascular endothelial growth factor administration does not improve microvascular disease in the salt-dependent phase of post-angiotensin II hypertension Am J Physiol Renal Physiol, December 1, 2006; 291(6): F1248 - F1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. I. Feig, M. Mazzali, D.-H. Kang, T. Nakagawa, K. Price, J. Kannelis, and R. J. Johnson Serum Uric Acid: A Risk Factor and a Target for Treatment? J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S69 - S73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nakagawa, W. Sato, Y. Y. Sautin, O. Glushakova, B. Croker, M. A. Atkinson, C. C. Tisher, and R. J. Johnson Uncoupling of Vascular Endothelial Growth Factor with Nitric Oxide as a Mechanism for Diabetic Vasculopathy J. Am. Soc. Nephrol., March 1, 2006; 17(3): 736 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Perez-Rojas, S. Derive, J. A. Blanco, C. Cruz, L. M. de la Maza, G. Gamba, and N. A. Bobadilla Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity Am J Physiol Renal Physiol, November 1, 2005; 289(5): F1020 - F1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shimizu, Y. Masuda, T. Mori, H. Kitamura, M. Ishizaki, Y. Sugisaki, and Y. Fukuda Vascular Endothelial Growth Factor165 Resolves Glomerular Inflammation and Accelerates Glomerular Capillary Repair in Rat Anti-Glomerular Basement Membrane Glomerulonephritis J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2655 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nakagawa, H. Y. Lan, H. J. Zhu, D.-H. Kang, G. F. Schreiner, and R. J. Johnson Differential regulation of VEGF by TGF-{beta} and hypoxia in rat proximal tubular cells Am J Physiol Renal Physiol, October 1, 2004; 287(4): F658 - F664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Basile, K. Fredrich, D. Weihrauch, N. Hattan, and W. M. Chilian Angiostatin and matrix metalloprotease expression following ischemic acute renal failure Am J Physiol Renal Physiol, May 1, 2004; 286(5): F893 - F902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Basile, D. L. Donohoe, K. Roethe, and D. L. Mattson Chronic renal hypoxia after acute ischemic injury: effects of L-arginine on hypoxia and secondary damage Am J Physiol Renal Physiol, February 1, 2003; 284(2): F338 - F348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Li, C. W. Yang, W. Y. Kim, J. Y. Jung, J. H. Cha, Y. S. Kim, J. Kim, W. M. Bennett, and B. K. Bang Reversibility of chronic cyclosporine nephropathy in rats after withdrawal of cyclosporine Am J Physiol Renal Physiol, February 1, 2003; 284(2): F389 - F398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Johnson, J. Herrera-Acosta, G. F. Schreiner, and B. Rodriguez-Iturbe Subtle Acquired Renal Injury as a Mechanism of Salt-Sensitive Hypertension N. Engl. J. Med., March 21, 2002; 346(12): 913 - 923. [Full Text] [PDF]
|
|
|
|
|
|
S.-I. Suga, M. I. Phillips, P. E. Ray, J. A. Raleigh, C. P. Vio, Y.-G. Kim, M. Mazzali, K. L. Gordon, J. Hughes, and R. J. Johnson Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity Am J Physiol Renal Physiol, October 1, 2001; 281(4): F620 - F629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Quiroz, H. Pons, K. L. Gordon, J. Rincon, M. Chavez, G. Parra, J. Herrera-Acosta, D. Gomez-Garre, R. Largo, J. Egido, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition Am J Physiol Renal Physiol, July 1, 2001; 281(1): F38 - F47. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
